Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Common Equity (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Common Equity data on record, last reported at $503.0 million in Q3 2025.

  • For Q3 2025, Common Equity fell 28.91% year-over-year to $503.0 million; the TTM value through Sep 2025 reached $503.0 million, down 28.91%, while the annual FY2024 figure was $671.6 million, 51.95% up from the prior year.
  • Common Equity reached $503.0 million in Q3 2025 per VRDN's latest filing, down from $515.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $707.5 million in Q3 2024 and bottomed at $98.9 million in Q2 2021.
  • Average Common Equity over 5 years is $379.8 million, with a median of $395.1 million recorded in 2022.
  • Peak YoY movement for Common Equity: skyrocketed 872.3% in 2021, then tumbled 30.67% in 2023.
  • A 5-year view of Common Equity shows it stood at $187.7 million in 2021, then skyrocketed by 110.46% to $395.1 million in 2022, then rose by 11.89% to $442.0 million in 2023, then skyrocketed by 51.95% to $671.6 million in 2024, then decreased by 25.11% to $503.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $503.0 million in Q3 2025, $515.2 million in Q2 2025, and $604.5 million in Q1 2025.